PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Negative revenue growth while ECL.AX stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-100.00%
Negative gross profit growth while ECL.AX is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
100.00%
EBIT growth of 100.00% while ECL.AX is zero. Bruce Berkowitz would see if small gains can be scaled further.
100.00%
Operating income growth of 100.00% while ECL.AX is zero. Bruce Berkowitz would see if this modest edge can become significant.
100.00%
Net income growth of 100.00% while ECL.AX is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
100.00%
EPS growth of 100.00% while ECL.AX is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
100.00%
Diluted EPS growth of 100.00% while ECL.AX is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
-100.00%
Share reduction while ECL.AX is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 10Y revenue/share CAGR while ECL.AX stands at 100.49%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
10Y OCF/share CAGR in line with ECL.AX's 100.80%. Walter Schloss would see both as similarly efficient over the decade.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Our R&D shrinks while ECL.AX invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
100.00%
SG&A growth of 100.00% while ECL.AX is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.